Table: Taisho Pharmaceutical HD -Q1 group results
Jul 29 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2019 Jun 30, 2018 Mar 31, 2020
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 60.26 61.75 293.50
(-2.4 pct) (-9.9 pct) (+12.2 pct)
Operating 8.32 8.16 33.00
(+2.0 pct) (+17.5 pct) (+5.7 pct)
Recurring 7.65 12.21 37.00
(-37.3 pct) (+38.8 pct) (-9.4 pct)
Net 11.01 13.69 29.50
(-19.6 pct) (+147.3 pct) (-39.3 pct)
EPS 137.91 yen 171.50 yen 369.64 yen
EPS Diluted 137.77 yen 171.35 yen
Ann Div 120.00 yen 110.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 70.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10